Latest Breaking News On - Atherosclerotic cardiovascular disease - Page 1 : comparemela.com

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Sandeep kulkarniSarah mishekDrug administrationExchange commissionDevelopment expensesTourmaline bio incBio reports first quarterRecent businessInitiated phaseInvestigational new drugAtherosclerotic cardiovascular diseaseExpanded thyroid eye diseaseChief executive officerUpcoming milestonesCorporate highlightsTourmaline bio

Indiana GOP Congressional Primary Won by Woman Who Passed Away 2 Months Ago

Indiana GOP Congressional Primary Won by Woman Who Passed Away 2 Months Ago
theepochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theepochtimes.com Daily Mail and Mail on Sunday newspapers.

United statesMarion countyMel gibsonGabe whitleyAndre carsonJennifer karemPhilip davisIndiana republican partyUs congressMembers of the christ cathedral churchMarion county coroner officeIndiana election divisionBiden administrationAssociated pressMarion county republican committeeOffice on feb

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively)1 A significantly greater proportion of the ASCVD patients receiving Leqvio achieved guideline-recommended LDL-C goal vs. the usual care arm […]

United statesSouth koreaNoord hollandMichael meoMarlena abdinoorMichael korenParag mahantiJonathan grahamSloan simpsonColl cardiolHealth promotion seriesAlnylam pharmaceuticalsAmerican heart associationEuropean medicines agencyNovartis pharmaceuticals corpAmerican college of cardiology congress

Novartis Pharma AG: New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

Novartis Pharma AG: New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaNoord hollandDennis riedlNicole zinsli sommSatoshi sugimotoRichard jarvisIsabella zinckImke kappesSloan simpsonMichael meoMarlena abdinoorParag mahantiJonathan grahamColl cardiolMichael koren

New Novartis data show early addition of twice-yearly*

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal.

United statesSouth koreaNoord hollandJonathan grahamRichard jarvisIsabella zinckSatoshi sugimotoNicole zinsli sommColl cardiolParag mahantiMichael meoImke kappesMichael korenMarlena abdinoorSloan simpsonAmerican heart association